Sense Diagnostics

Sense Neuro Diagnostics, founded in 2016 and based in San Francisco, is pioneering a novel diagnostic modality for time-sensitive brain injuries. Its investigational NeuroHawk™ device performs a 2.5-second scan of the cranial vault to identify hemorrhagic stroke, large vessel occlusion (LVO), and other brain bleeds, addressing critical gaps in pre-hospital triage and in-hospital monitoring. The company is currently conducting a pivotal FDA trial for its hospital monitor with a goal of clearance, while also developing earlier-stage field assessment versions for military and EMS use. Its technology aims to reduce disability and death by accelerating proper treatment pathways.

Non-invasive brain scanning using a multi-antenna array that transmits safe, low-power radio frequency (RF) pulses. The system detects alterations in RF signals caused by the unique electrical properties of healthy versus pathological brain tissue (e.g., hemorrhage, ischemia).

Sense competes against the entrenched standard of care (CT/MRI) and other companies developing portable neurodiagnostic tools, such as those using transcranial Doppler, EEG analysis, or other biophysical signatures. Its key differentiator is the claimed speed (2.5 seconds) and ability to differentiate stroke subtypes non-invasively.